Corporate Vaccsheet

Intravacc

Version: October 2022

Netherlands-based global CDMO
- Founded in 2013
- HQ at Utrecht Science Park Bilthoven
- Private company since 2021
- ~100 FTEs
- Leading OMV company

State-of-the-art facilities
- 1500+ m^2 laboratories, incl. BSL-2 & GMP
- GMP certified
- ISO 14001:2015 certified
- In-house QA, QC and QP

Business focus
- Offering specialised CDMO services
- One-stop-shop for vaccine development
- Platforms & vaccines for partnering
- Bridge between bench- and large-scale manufacturing

Our proprietary scalable platform technologies

OMV
- Bacterial
- Viral

Cell-based viral
- Vero and HEK293
- Viral (vector)

Conjugation
- Infectious diseases
- Combination with OMV

Adjuvant
- OMV
- LPS

Distinctive technology
- 4 proprietary vaccine platforms
- 11 patent families
- Viral rescue
- Mass spectrometry
- Intranasal vaccine development

In addition we offer
- Medium design
- Higher order structural analysis
- Physiochemical and immunological analysis
- Bench- and pilot-scale GMP

Stellar track record
- 2 OMV vaccines licensed
- 1 conjugate AMR vaccine licensed
- 3 cell-based viral vaccines licensed
- 300+ scientific publications
- 50+ customers worldwide
- >10 partnerships

Our services - from discovery to clinical proof of concept



Board of Directors
- Dr. Jan Groen, CEO and Chairman
- Mrs. Nathalie Laarakker, CFO

Executive Management
- Dr. Danielle Lankveld, COO
- Prof. Dr. Virgil Schijns, CSO
- Dr. Maj-Britt Kaltoft, CBO

Supervisory Board
- Mr. Nico Oudendijk, Chairman
- Mr. Bruno Bruins
- Dr. Karin Dorrepaal

Intravacc
Innovating vaccines

Intravacc B.V.
Utrecht Science Park Bilthoven – Antonie van Leeuwenhoeklaan 9 – 3721 MA Bilthoven – The Netherlands
intravacc.nl

Our vaccine development pipeline

Vaccine	Target	Platform	Stage: Pre-clinical	Phase I	Phase II
Avacc 17®	Hib	Conjugation	Marketed		
Avacc 13®	MenB	OMV			
Avacc 10®	Covid-19	OMV			
Avacc 11®	Gonorrhea	OMV			
Avacc 3®	Pertussis	OMV			
Avacc 5®	EV D68	Cell			
Avacc 2®	HFMD	Cell			
Avacc 7®	Lyme	OMV			

Avacc 2® HFMD
- First-in-class quadrivalent vaccine
- Strong VNT titers
- GMP seed lots produced for 3 strains

Avacc 3® Pertussis
- Broad protection
- Good safety profile
- Superior over whole cell and acellular vaccines in mice

Avacc 5® EV D68
- High VNT in mice
- GMP seed lot produced
- Production process being scaled up

Avacc 7® Lyme
- Borrelial antigens expressed on OMV platform
- Strong antibody response
- Clearance in mouse challenge model

Avacc 10® Covid-19
- Intranasal
- Good safety and tolerability profile
- Phase I starts Q4 2022

Avacc 11® Gonorrhea
- First in class
- Effective in animal models
- Co-developed with Therapyx

Avacc 13® MenB
- Nona-valent PorA vaccine
- Performed superior in *in-silico* studies over marketed vaccines

Avacc 17® Hib
- Cost effective and efficacious
- Marketed in India and China
- Other regions available for partnering

Learn more
Are you interested in our CDMO services or pipeline products?
Our team is happy to discuss all possibilities with you.

Get in touch!
email us at: bd@intravacc.nl

Intravacc
Innovating vaccines

Intravacc B.V.
Utrecht Science Park Bilthoven – Antonie van Leeuwenhoeklaan 9 – 3721 MA Bilthoven – The Netherlands
intravacc.nl